Lipoprotein(a): What to know about elevated levels

When a U.S. government health institute publishes a plain-language explainer on a niche lipid, it’s a signal the topic is about to matter to everyone. This NHLBI feature on lipoprotein(a) is exactly that.

Its messages are crisp and aimed at a broad audience: Lp(a) behaves like LDL but adds pro-clotting properties that make it more dangerous; 20–30% of people have elevated levels; it’s the leading inherited cardiovascular risk factor — more heritable than hypertension, diabetes, or obesity; and because levels are genetically fixed, a single lifetime measurement suffices. No Lp(a)-specific drug is approved yet, but Phase 3 trials are underway, and PCSK9 inhibitors lower it modestly.

The practical takeaway is who-to-test guidance: adults with early heart attacks, a family history of premature disease, or statin-resistant LDL — with some bodies favoring testing everyone once. For now, management means aggressive control of every modifiable risk factor.

We rate the evidence solid for what it is: an authoritative NHLBI feature quoting recognized experts and accurately reflecting the science, though a general-audience piece rather than a systematic review. Its clinical significance is high and timely — it’s pushing awareness of an underused test just ahead of therapies that could change everything. The status quo it pushes against is real: U.S. Lp(a) testing badly lags Europe and Canada.